COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies
- PMID: 33464914
- DOI: 10.1021/acs.molpharmaceut.0c00608
COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies
Abstract
At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a global pandemic, was identified in the Chinese city of Wuhan. Although unique in its transmission and virulence, COVID-19 is similar to zoonotic diseases, including other SARS variants (e.g., SARS-CoV) and MERS, in exhibiting severe flu-like symptoms and acute respiratory distress. Even at the molecular level, many parallels have been identified between SARS and COVID-19 so much so that the COVID-19 virus has been named SARS-CoV-2. These similarities have provided several opportunities to treat COVID-19 patients using clinical approaches that were proven to be effective against SARS. Importantly, the identification of similarities in how SARS-CoV and SARS-CoV-2 access the host, replicate, and trigger life-threatening pathological conditions have revealed opportunities to repurpose drugs that were proven to be effective against SARS. In this article, we first provided an overview of COVID-19 etiology vis-à-vis other zoonotic diseases, particularly SARS and MERS. Then, we summarized the characteristics of droplets/aerosols emitted by COVID-19 patients and how they aid in the transmission of the virus among people. Moreover, we discussed the molecular mechanisms that enable SARS-CoV-2 to access the host and become more contagious than other betacoronaviruses such as SARS-CoV. Further, we outlined various approaches that are currently being employed to diagnose and symptomatically treat COVID-19 in the clinic. Finally, we reviewed various approaches and technologies employed to develop vaccines against COVID-19 and summarized the attempts to repurpose various classes of drugs and novel therapeutic approaches.
Keywords: COVID-19; SARS-CoV-2; therapeutic strategies; transmission; vaccines.
Similar articles
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
-
Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.Drug Dev Res. 2021 Feb;82(1):12-26. doi: 10.1002/ddr.21720. Epub 2020 Jul 30. Drug Dev Res. 2021. PMID: 33216381 Review.
-
Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.Annu Rev Microbiol. 2021 Oct 8;75:19-47. doi: 10.1146/annurev-micro-110520-023212. Epub 2021 Jan 25. Annu Rev Microbiol. 2021. PMID: 33492978
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
-
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949. Cells. 2021. PMID: 34831172 Free PMC article. Review.
Cited by
-
Multiomics Reveals a Mechanism: Glycogen Synthesis, Galactose Metabolism, and Ethanol Degradation Pathways, the Durable Role of Neutralizing Antibodies in Preventing COVID-19.ACS Omega. 2024 Oct 10;9(42):42757-42765. doi: 10.1021/acsomega.4c04047. eCollection 2024 Oct 22. ACS Omega. 2024. PMID: 39464477 Free PMC article.
-
Economic evaluation of vaccination against COVID-19: A systematic review.Health Sci Rep. 2024 Feb 7;7(2):e1871. doi: 10.1002/hsr2.1871. eCollection 2024 Feb. Health Sci Rep. 2024. PMID: 38332928 Free PMC article.
-
Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS-CoV-2.Microbiol Spectr. 2022 Oct 26;10(5):e0239822. doi: 10.1128/spectrum.02398-22. Epub 2022 Sep 28. Microbiol Spectr. 2022. PMID: 36169448 Free PMC article.
-
The COVID-19 pandemic - How many times were we warned before?Eur J Intern Med. 2022 Nov;105:8-14. doi: 10.1016/j.ejim.2022.07.009. Epub 2022 Jul 18. Eur J Intern Med. 2022. PMID: 35864073 Free PMC article. Review.
-
Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19.Front Oncol. 2022 Jun 8;12:921587. doi: 10.3389/fonc.2022.921587. eCollection 2022. Front Oncol. 2022. PMID: 35756668 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous